Hone Health Raises $228M | $200M Is General Catalyst Growth Financing

Hone Health raised $228M: a $28M Series A extension led by MarcyPen Capital Partners plus $200M in growth financing from General Catalyst's Customer Value Fund.

By the Numbers

$228M
Hone Health total financing, Nov 2026
$28M
Hone Health Series A extension (equity)
$200M
General Catalyst CVF growth financing
$65M
Hone Health total equity raised
200,000+
Hone Health patients treated
Trace Cohen
By Trace Cohen · Value Add Pulse Funding Desk
Founder & Editor-in-chief, Value Add VC
3 min read
Hone Health Raises $228M | $200M Is General Catalyst Growth Financing: key figures
ShareXLinkedInEmail

THE RUNDOWN

1

Only $28M of Hone Health's $228M headline is equity; the other $200M is growth financing, so the dilution is far smaller than the headline suggests

2

General Catalyst's Customer Value Fund is now funding the marketing of consumer health companies, after a $500M commitment to Nooks earlier this month

3

Hone Health says it has treated more than 200,000 patients, the kind of repeatable customer data that growth-financing lenders underwrite

4

Hone Black, a 1,600-marker concierge membership, moves Hone Health from hormone clinic toward the premium longevity tier

The VC Read

Value Add VC analysis

Read this as a $28M round with a $200M marketing credit line attached. The diligence item is cohort payback: how many months of membership revenue it takes to earn back the cost of acquiring a Hone patient. That number decides whether the CVF money is cheap growth or a fixed claim on revenue that crowds out the next equity round.

Analysis

As of November 18, 2026, Hone Health has raised $228 million, but most of it is not venture equity, per the company's announcement. MarcyPen Capital Partners led the round.

  • Equity: "$28M in equity as a Series A financing"
  • Growth financing: "$200M in growth financing from General Catalyst's Customer Value Fund (CVF)"

What does Hone Health do?

Hone Health is a direct-to-consumer, physician-led longevity company. It sells biomarker testing, physician consultations and personalized treatment across menopause, weight management, thyroid, heart health and sexual health, MedCity News reported. Saad Alam is co-founder and CEO. The company says it has treated more than 200,000 patients, administered 750,000 tests and processed 25 million health markers.

“The company says it has treated more than 200,000 patients, administered 750,000 tests and processed 25 million health markers.”

Alongside the raise, Hone launched Hone Black, a concierge membership built on testing of more than 1,600 health markers plus ongoing physician care. Hone says the program ran in stealth for a year. The new money goes to five areas: programs in metabolic health, PMOS, inflammation and immunity; diagnostics such as full-body MRI, DEXA, coronary CT angiography and gut microbiome analysis; AI-enabled clinical tools; a physician-supervised peptide program; and research and trials.

How much has Hone Health raised?

Per the release, the new equity tranche extends Hone Health's $33 million Series A, announced in January 2025, and brings total equity funding to $65 million; the release does not itemize the funding beyond those two tranches. That $65 million is the venture capital in the business; the CVF money is growth financing on top of it. No source we opened states a Hone Health valuation.

Who invested in Hone Health

MarcyPen Capital Partners led the round. The release says MarcyPen has backed Hone for more than two years and led its earlier Series A, a role that had not been disclosed before. Pentland Ventures, Kinship Ventures, Hanwha, Gannet Capital, humbition, Comma Capital and ID Ventures joined the extension. Kinship Ventures was co-founded by Gwyneth Paltrow and Moj Mohdara. David Grutman joined as a strategic investor and advisor, and individual backers include Nick Jonas, Joe Jonas, Kevin Jonas and Kelly Rowland.

Why the General Catalyst money is different

General Catalyst's Customer Value Fund does not buy a stake the way a Series B lead would. It funds customer acquisition and earns a return from the revenue those customers bring in. Pulse covered the CVF's $500M commitment to Nooks on November 4. Hone is a newer use of the same structure, applied to a consumer health subscription instead of B2B sales software. In longevity, Pulse previously covered Function Health's $450M growth financing, the closest comparable in our archive.

Value Add VC data

  • Jan 2025, Series A -- $33M, valuation not disclosed, led by MarcyPen Capital Partners (Fitt Insider)
  • Nov 2026, Series A extension -- $28M equity, valuation not disclosed, led by MarcyPen Capital Partners (Fitt Insider)
  • Nov 2026, growth financing -- $200M from General Catalyst's Customer Value Fund (MedCity News)

Comparable deals: Nooks, $500M CVF commitment (Nov 2026); Function Health, $450M growth financing. No valuation is disclosed, so we cannot give a markup multiple.

The catch in a $228M headline

Growth financing works only while the numbers hold. If the cost of acquiring a patient rises or members cancel sooner than modeled, the CVF capital becomes expensive, and Hone has $65 million of total equity funding, per the release, not $228 million, as its cushion. Hone has disclosed no revenue, retention or pricing for Hone Black. Its new peptide and diagnostics programs also bring it into areas where regulators and payers are still setting the rules for direct-to-consumer care.

ShareXLinkedInEmail

More from the Pulse archive: Startup & VC Funding coverage → · All topics

Key Sources

1 source

THE WIRE in your inbox— Tech, startup & VC news with The VC Read, a few times a week. Free to subscribe, no spam.

No spam, unsubscribe anytime. Sent via Substack · Privacy · or subscribe on Substack ↗